Explore the latest news from Khondrion and its team.
Published: 25 November 2014 Khondrion has received an Orphan Drug Designation from the FDA of its frontrunner compound KH176, in the treatment of...
Read the interview on pharmaboardroom.com Interview: Jan Smeitink – CEO, Khondrion, The Netherlands Jan Smeitink, CEO of...
Khondrion Welcomes Hans Schikan, Former Prosensa CEO, to Advisory Board August 10, 2015, NIJMEGEN – Khondrion, the Dutch...
